Introduction
The WAS gene is mutated in Wiskott-Aldrich syndrome (WAS) and in X-linked thrombocytopenia. These diseases are characterized by platelet defects with variable immune dysfunction, as a result of abnormal signaling and impaired cytoskeletal regulation in hematopoieitic cells. 1 The WAS protein (WASp) is expressed exclusively in hematopoietic cells, where it functions as a regulator of actin cytoskeleton reorganization, by linking various types of signals to Arp2/3-mediated actin polymerization. 2, 3 In T cells, WASp is an essential component of the signal transduction cascade initiated by T-cell receptor engagement, contributing to the establishment of immunological synapse and T-cell activation. 4, 5 In highly motile cells such as dendritic cells (DC), WASp is essential for motility and for the formation of podosomes that are actin-rich highly dynamic cytoskeletal structures. 6, 7 Several groups have demonstrated that gene transfer, via Moloney-derived gammaretroviral vectors (MLV-RV) or via HIV-1-derived lentiviral vectors (HIV-LV), effectively restores protein expression and corrects the defects in cytoskeletal organization, cellular activation and inflammation in various in vitro or in vivo models of WAS 5, 6, [8] [9] [10] [11] [12] [13] [14] [15] These studies provide a strong rationale to develop clinical gene therapy protocols for this disease. The advanced generations of HIV-LV are self-inactivating (SIN) constructs that regulate the expression of the transgene through an internal promoter. This safety feature provides the opportunity to use cellular promoters that may provide a physiological regulation of transgene expression. Normally, WASp is expressed in all leukocyte lineages and found only in the hematopoietic system. Two recent studies have demonstrated in the context of SIN LV that either a 1.6 kb fragment or a shorter 0.5 kb fragment corresponding to the WAS 5 0 flanking regions, function well in T cells and are otherwise weakly active in non-hematopoietic cells. 12, 14 Further studies were therefore warranted to evaluate the activity of these two WAS promoters in an equivalent vector backbone, in multiple lineages of hematopoietic cells and in comparison with previously tested constitutive internal promoters. For example, the ubiquitouslyactive PGK-1 promoter is known to induce WASp expression in vitro in T cells derived from WAS patients 12 and in vivo in WASp knockout mice after engraftment of transduced hematopoietic progenitor cells. 13, 15 Other internal promoters have also been successfully used in HIV-LV to express genes in hematopoietic cells, including a short intron-less EF1-alpha promoter 16 and the spleen focus forming virus (SFFV) viral promoter, 17 which, in particular, is capable of expressing WASp in human DC. 18 Our results showed that all lentiviral WASp expression systems worked efficiently in multiple hematopoietic lineages. Although transcriptionally weaker, the WAS promoters restored sufficient levels of WASp to correct the defects in patients' T cells and DC. The transduction of patient's CD34 + progenitor cells also led to a restoration of WASp expression without measurable toxicity.
Results

Generation of WAS-LV utilizing various internal promoter elements
To optimize a WAS gene expression cassette, we compared the performance of several internal promoters driving the expression of human WAS cDNA in the context of an identical lentiviral backbone. The pRRL SINcPPT/CTS vector is an advanced generation SIN and Tat-independent HIV-LV system, which produces high titers and has successfully been used to transduce various types of cells. 19 Using this backbone, several human WAS cDNA expression cassettes were constructed, varying the internal promoter to include the human short intron-less EF1-alpha promoter, the SFFV LTR promoter or WAS promoter fragments consisting of 1.6 or 0.5 kb of the 5 0 flanking sequences of the WAS gene from the start of transcription ( Figure 1 ). The corresponding LV (W0.5, W1.6, PGK, EF1, SFFV) were pseudotyped with VSV-G and were produced to equivalent titers, being on average 6.975 Â 10 9 infectious genome (i.g.)/ml and 7.276.4 Â 10 4 ng p24/ml (n ¼ 17 total, at least two separate batches produced per vector). Each vector was functional, efficiently inducing WASp in a high proportion of WAS B-lymphoblastic cell lines (B-LCL) (60-80% of normal levels) ( Figure 2a ). As expected from prior studies, 12, 14 the W1.6 and W0.5 LV induced very little WAS transgene expression in non-hematopoietic cells. Less than 20% of HCT116 (epithelial carcinoma), HT1080 (fibrosarcoma) or 293T cells (embryonic kidney) expressed WASp following transduction with high concentrations of the W0.5 and W1.6 vectors (data not shown). In contrast, high frequencies of WASp-expressing cells were induced following transduction with the PGK, EF1 and SFFV vectors utilizing ubiquitously active promoters. Altogether these data validate the different vectors and confirm the hematopoietic-restriction of WAS promoters.
Activity of WAS-LV utilizing various internal promoter elements in B-LCL
The various promoter systems induced WAS gene expression in WAS B-LCL that were derived from three different patients (04W, 08W and 010W) ( Table 1) . In all cases, WAS mRNA and protein levels were copy number-dependent (Figure 2a and b) . The WAS promoters appeared to be transcriptionally weaker than the other promoters since lower levels of mRNA were produced following transduction with the W0.5 or W1.6 vectors compared to the PGK, EF1 or SFFV vectors, for equivalent transgene copies integrated per cell (Figure 2a ). The levels of protein expression achieved seemed to be comparable from one vector to another as measured by Western blot analysis or by the percentage of WASp + cells. For clarity, Figure 2b compares various concentrations of W0.5, W1.6 and PGK vectors. In spite of a high concentration of vector and multiplicity of infection (MOI), none of the conditions tested was able to induce protein overexpression and, in particular, there appears to be a saturation of protein expression following transduction with the two highest concentrations of PGK vector. This is illustrated also by a representative fluorescence-activated cell sorter (FACS) analysis of the 08W B-LCL line transduced with the W1.6 vector 
Activity of WAS-LV utilizing various internal promoter elements in T cells
A T cell line was established from patient WAS1 ( (Figure 3a) showed that each vector induced WASp expression in a dose-dependent manner. Vectors PGK, EF1 or SFFV induced higher levels of WASp than W0.5 and W1.6. The incomplete restoration of WASp expression in the T-cell cultures compared to healthy control cells was related to limited percentages of transduced cells (Figure 3b ). Intracytoplasmic WASp staining and FACS analysis showed that at the MOI of 20, the initial percentage of WASp + cells was low and ranged from 9% (W0.5) to 26% (PGK), therefore consistent with the low and variable range of protein levels detected by Western blot. Following transduction at the MOI of 100, the initial percentage of WASp + cells was higher for all vectors and ranged from 16% (W1.6) to 45% (SFFV), correlating also with the Western blot analysis. These results are consistent with the measures of integrated vector per cell and suggest that the differences of WASp expression levels observed after transduction with the different vectors were due in part to different transduction efficiencies. Transduced WAS T-cell populations were cultured for several weeks to check that WASp expression was sustained over time. Except for the WAS T cells transduced with the W0.5 vector at the MOI of 20 for which WASp expression was not detectable, all transduced WAS T-cell populations expressed the transgene during the 10 weeks of culture. Remarkably, the fraction of WASp + cells increased over time in all transduced conditions (Figure 3b ). At week 10 of culture, the proportion of WASp + cells ranged from 33 to 68% for the T cells transduced at the MOI of 20, and from 35 to 72% for the T cells transduced at the MOI of 100. These results provide additional evidence for a selective in vitro growth advantage of transduced WAS patients' T cells over their untransduced counterparts, as previously reported. 12, 14 To further compare the activity of the short or long WAS promoter sequences in T cells, we tested the corresponding LV in a model of WASp-deficiency created in Jurkat T cells by RNA interference. We have previously described a LV (W8) encoding a small hairpin RNA that targets the 3 0 UTR of the WAS gene and stably inhibits 85-90% of WASp in Jurkat T cells. 18 This system allows WASp protein to be re-expressed when cells are transduced with a WASp-encoding LV such as SFFV, which does not encode the region targeted by the shRNA. 18 To compare the activity of the 0.5 and 1.6 kb promoter sequences in the context of otherwise identical 3 0 and 5 0 sequences of the WAS cDNA, we constructed two LV gene transfer cassettes expressing the longer cDNA (1585 nucleotides) either under control of the WAS 1.6 or 0.5 kb promoter to produce respectively the W1.6ex12 and W0.5ex12 vectors, which we used only in this set of experiments. Transduction of Jurkat-W8 cells with increasing concentrations of these two vectors, induced equivalent re-expression of WASp, and in both cases restored the levels found in parental Jurkat cells (reaching 120% of parental levels with the highest concentration of vector) ( Figure 4 ). The main point here is that the short or long WAS promoter seem to function equivalently in this T-cell model. Besides, these results provide additional evidence of efficacy of the WAS promoters in the human T-cell lineage.
12,14
Functional restoration obtained after transduction of WAS T lymphocytes
As shown in Figure 5 , WAS patient's T cells display profound defects in their ability to proliferate and to produce interleukin-2 in response to TCR stimulation. To determine the efficacy of the various LV gene expression cassettes to correct these parameters, we measured the response of WAS T cells to anti-CD3 mAbs after transduction and after a period of culture of 8 weeks. Based on data in Figure 4b , this period of time favors the expansion of the fraction of WASp-expressing T cells in the culture. WAS T cells transduced with any of the five different LV tested increased their response to anti-CD3 antibody stimulation with a dose-dependent proliferation and IL-2 production ( Figure 5 ). The data were roughly segregated along two groups, according to vector dose. The group corresponding to MOI 20 (dotted lines) provided intermediate levels of restoration of proliferation and IL-2 whereas the group corresponding to MOI 100 (plain lines) displayed high levels of activity, close to that observed in normal T cells. Therefore, at 
Comparison of WASp expression and functional restoration obtained in dendritic cells
The lack of WASp induces defects not only in lymphocytes but also in antigen-presenting cells, which are likely to contribute to the immune dysfunction of WAS.
To evaluate the efficacy of the WAS gene expression vectors in DC, we transduced bone marrow (BM)-derived immature DC cultures obtained from patients 04W and 07W with 1 Â 10 8 i.g./ml of W0.5, W1.6 or PGK LV. Equivalent levels of WAS mRNA were induced by each of the LV, being approximately 100-fold higher than in untransduced cells, as determined in one experiment (data not shown). The lack of WASp is known to cause marked cytoskeletal anomalies in DC. 20 Normally, these cells elaborate podosomes that form upon cell-substrate contact and consist of a ring of approximately 0.5 mm diameter containing vinculin and actin. 21 Podosomes are absent in DC or macrophages of WAS patients. 22 Only 272% of immature DC prepared from either the 04W or 07W patient could produce recognizable podosomes upon adherence onto fibronectin, whereas normal control cultures contained approximately 50-60% of cells with podosomes. Figure 6A shows representative results obtained after transduction of DC from patient 04W in which we found respectively 1671, 1671 and 1871% cells with podosomes after transduction with the W0.5, W1.6 and PGK LV, respectively. All three LV tested were capable of inducing DC that assembled 20 or more podosomes per cell, indicating that such cells probably contained near normal amounts of WASp. Figure 6B illustrates the cellular structures and shows that classic clusters of podosomes were obtained after transduction of WAS DC, resembling those of DC from normal individuals. 21 Similarly to T cells, the overall numbers of functionally corrected DC were lower than those obtained in DC from normal individuals as a result of incomplete transduction of the whole-cell population (data not shown). Probably, our transduction protocol for DC is not optimal. 23 Overall, the results show that all of Figure 7a . The 2-exposure protocol that resulted in higher vector copies (4.8 copies per cell) was estimated to provide approximately 80% of the WASp found in normal BM CD34
+ cells compared to the 1-exposure method (1.1 copies per cell) providing approximately 50% of normal protein levels. Transduction with W1.6 LV had no detrimental effect on CD34 + cell growth or survival (data not shown). The hematopoietic differentiation of transduced WAS CD34 + cells was normal in clonogenic assays as measured by the numbers of erythroid, myeloid or mixed colonies produced ( Table 2) . The appearance and size of colony-forming unit (CFU) colonies derived from WAS CD34 + cells untransduced or transduced with W1.6 was found to be normal (Supplementary data S1). A second sample of CD34 + cells was obtained from patient WAS5. These cells were transduced with the 1-exposure protocol using a slightly higher concentration of LV (5 Â 10 7 i.g/ml MOI ¼ 400). The W0.5 and W1.6 vectors were compared and found to provide equivalent levels of transduction with 3.1 and 3.7 copies per cell, respectively. WASp expression in individual cells was measured by FACS ( Figure 7b ) and about 30% of the cells treated with W0.5 or W1.6 was positive. While this may seem partial, these percentages are similar to those of normal umbilical cord blood (UCB) CD34 + -derived cells, thus indicating that the vectors induced near normal levels of WASp expression. Western blot analysis confirmed high levels of restored WASp following transduction with either vector, with an estimate of about 70% of the levels of UCB control cells (Figure 7c) . Altogether, these data show that gene transfer into BM progenitor cells from WAS patients can be achieved efficiently. The W0.5 and W1.6 vectors functioned comparably. Both induced practically normal levels of WASp with the integration of relatively few (3) copies of vector per cell. Figure 4 . After 8 weeks, the anti-CD3-mediated proliferative response was measured by 3 H-Thymidine incorporation, and IL-2 production in the medium was measured by ELISA.
Efficient, targeted vectors for WAS S Charrier et al
Lack of hematopoietic toxicity of WAS gene transfer in CD34 + cells
To assess the risk of toxicity associated with the potential overexpression of WASp, we transduced CD34 + cells obtained from normal UCB or BM (Table 3) with the various WASp-encoding LV using relatively high concentrations of vector particles (2 to 10 Â 10 7 i.g./ml), which introduced between 0.5 to two copies of viral genome per cell (data not shown). FACS analysis of the control culture treated with the GFP-encoding LV showed that 35-45% of the cells were transduced (n ¼ 3 experiments). Growth and hematopoietic colony formation were not significantly impaired by transduction with 
Discussion
In order to develop a safe and effective LV gene transfer cassette for gene therapy of WAS, we assessed the potential of several internal promoters to regulate expression of a human WAS cDNA transgene in multiple hematopoietic cell lineages and induce correction of the cellular anomalies. We used the pRRL cassette which had already demonstrated its efficacy to express a human WAS cDNA under control of the PGK-1 promoter or of the native 1.6 kb WAS gene promoter sequence, both in vivo in murine hematopoietic progenitor cells 13, 15 and in WAS T lymphocytes in vitro. 12 Here, we extend these results by showing that several other internal promoters can be used in the pRRL backbone to express the human WAS cDNA in lymphoid and myeloid cells. Some of the promoters appeared to be transcriptionally stronger, as observed in B cells where higher levels of mRNA were induced from the EF1-alpha, SFFV or PGK-1 compared to WAS promoters. Yet, at equivalent levels of transduction, promoter usage made little difference in total amounts of protein produced by the cells or in the frequency of cells capable of expressing the protein after transduction of T or B lymphocytes. In addition, equivalent levels of functional correction were obtained in T cells and DC obtained from WAS patients. There may be several reasons to explain why differences between the promoters were observed at the mRNA level but not at the protein or at the functional level. One reason may be that Q-reverse transcription-polymerase chain reaction (Q-RT-PCR) is a more discriminative technique than Western blot or functional testing. Alternatively, the lower transcriptional strength of the WAS promoters could be partially compensated by a relative stability and accumulation of WASp in the cells after transduction. Regardless of the mechanism, we find that globally, the LV gene expression system tested here is efficient with any one of the internal promoter used. Transduction can lead to a reconstitution of protein levels that can be estimated to be between 50 and 80% of normal levels. In T lymphocytes, one round of transduction can achieve near complete functional restoration of IL-2 production.
A main point of our study is that it validates the efficacy of gene expression cassettes utilizing native WAS promoter sequences in vitro in multiple lineages of patients cells including hematopoietic progenitor cells. Two putative promoter regions have previously been identified for WAS in the human genome. 24, 25 The strongest is a proximal promoter that starts immediately upstream of the transcription start site. Progressive 5 0 deletions from an initial 1.6 kb fragment of the WAS 5 0 flanking region have identified shorter fragments that are also active in CAT reporter assays, including a 0.5 kb Abbreviations: BFU-E, burst forming unit erythroid; BM, bone marrow; CFU-C, colony-forming units in culture; CFU-E, colony-forming-unit erythroid; CFU-GM, colony-forming-unit granulocyte macrophage; LV, lentiviral vectors; WAS, Wiskott-Aldrich syndrome. BM CD34 + cells from patient WAS4 were transduced with the W1.6 LV using either 1-exposure or 2-exposure protocol. Controls included a mock-transduction on CD34+ cells from WAS4 patient or from a normal BM donor. Cells were then tested in CFU-C assay to determine if W1.6 transduction affected hematopoietic differentiation potential. Photographs of colonies corresponding to this experiment are shown in Supplemental figure S1. ND ¼ normal donor. Figure S2) . In the present study, we tested the 0.5 or 1.6 kb 5 0 flanking regions of WAS, since these two fragments have been previously tested into LV expression systems and validated in human T cells. 12, 14 Possibly, shorter fragments could also be used as internal promoters and this could be addressed in a separate study. Our present results extend prior findings by presenting evidence that both WAS promoters function not only in human T lymphocytes but also in human B cells, dendritic cells and CD34 + cells. This confirms earlier studies, notably studies using GFP as a reporter system to show that the WAS 0.5 kb promoter is active in all types of human myeloid cells, 14 and data obtained in vivo in mice showing that the 1.6 kb WAS promoter functions in T and B lymphocytes as well as in platelets and myeloid cells. 15 The WAS proximal promoter is TATA-less and contains several Ets sites that may be responsible for regulating its expression in hematopoietic cells 25 although a detailed understanding of this restriction is not available yet. Indeed, we find here that the WAS promoters are poorly active in non-hematopoietic cells in agreement with prior results. 12, 14 This feature is adequate to restrict transgene expression to the compartment of cells targeted in the context of the gene therapy of WAS. In addition, this could be useful for other applications requiring the restriction of transgene expression to the hematopoietic system. In the assays performed, we were not able to detect differences in the activity of the short or long WAS promoter sequences in terms of levels of transgene expression and functional correction. An in silico analysis of these two sequences using the GenBank, JASPAR and TFBS resources 26, 27 showed that they both contain putative Ets, PU.1, c-Rel, Rel-A, Spi-1, Spi-B, Yin-Yang and MZF1-4 binding motifs. The Ets, PU.1 and Rel sites were previously reported and proposed to contribute to the regulation of WAS expression in hematopoietic cells. 25 The longer WAS promoter also contains additional putative MZF1-4 and GATA-3 sequences, which may play an important role, albeit entirely speculative at this point, in the regulation of WAS expression in T cells or myeloid cells (Supplementary Figure S2 ). Additional studies may therefore be needed to distinguish if the short or long WAS promoters lead to functionally distinct outcomes in models of gene therapy of WAS.
For the first time, we show that WAS patient's CD34 + cells can be efficiently transduced with the VSV-gpseudotyped pRRL LV system and that physiological levels of transgene can be achieved with WAS promoters.
In particular, the present data validate the ability to restore WASp expression in patients' CD34 + cells while preserving their in vitro differentiation potential, two important requisites for clinical use. The potential for hematopoietic toxicity induced by WASp-encoding vectors seems limited. Transduction of normal hematopoietic progenitor cells expressing WASp with the various vectors did not affect their short-or long-term hematopoietic differentiation potential into myeloid and erythroid lineages. A toxicity-limiting factor could be the inability to over-express high levels of WASp as observed in several experiments within the range of concentrations and MOI tested. Altogether, these results concur with successful prior gene therapy studies in mice.
10,13,15,28 to suggest the feasibility and possible efficacy of ex vivo gene therapy of WAS through transduction of hematopoietic progenitor cells. Several types of viral vectors can be used to express the WAS transgene. 5, 6, [8] [9] [10] [11] [12] [13] [14] For several reasons, HIV-LV are good candidates for ex vivo gene transfer into hematopoietic stem cells. Contrary to MLV-RV, HIV-LV integrate into non-dividing hematopoietic stem/progenitor cells under conditions of limited preactivation with cytokines which are more likely to preserve long-term multilineage hematopoietic reconstitution and the sustained expression of transgene. 29, 30 Contrary to MLV-RV, which are biased for promoter-proximal integration, HIV-LV appear to integrate throughout transcriptional units 31 and this may reduce the risk of insertional mutagenesis following transduction of hematopoietic stem/progenitor cells, although this is not demonstrated. The risk of insertional mutagenesis is not easily addressed, particularly in human cells as there are no experimental methods and insufficient clinical data. However, the tumor-prone Cdkn2a
À/À mouse model appears to be a sensitive assay and it provided direct experimental evidence that SIN HIV-LV have low genotoxicity even upon integration of about six copies of vector per cell. 32 In contrast, LTR-active MLV-RV were found to carry a significant risk of genotoxicity. The SIN design is therefore probably a key element that reduces this risk by providing the opportunity to use cellular promoters that have less long range enhancer activity than viral LTRs. Furthermore, by reducing the possibility of expression in non-hematopoietic cells, WAS promoters should reduce the risk of toxicity associated with ectopic or illicit expression of a cytoskeletal regulator. For these reasons and because the present study provides evidence of the efficacy of both the W 0.5 and W 1.6 vectors in various types of patients' cells including, B, T and DC and CD34+ cells, vectors with WAS promoters appear to be good candidate vectors to pursue for the development of a gene therapy protocol for WAS.
Materials and methods
Constructions
The different WAS cDNA-encoding gene transfer cassettes are described in Figure 1 . All include human WAS coding sequences that start at the ATG in position 35 of the reference sequence GenBank Accession Number NM_000377. The pRRL SIN cPPT/cTS W 1.6-hWASp-WPRE plasmid, described previously as pRRLW1.6pWW 12 and corresponding to vector W1.6, contains the 1508 nucleotides of the entire coding sequence. All other plasmids contain 1585 nucleotides of WAS cDNA as they further extend 3 0 of the stop codon by 77 nucleotides. These plasmids, pRRL SIN cPPT/cTS W0.5-hWASp-WPRE (vector W0.5), pRRL SIN cPPT/cTS EF1a-WASp-WPRE (vector EF1) and pRRL SIN cPPT/ cTS SFFV-WASp-WPRE (vector SFFV) were produced from the pRRL SIN cPPT/cTS PGK-WASp-WPRE plasmid (which was described as HIV-PGK-WASP 13 and corresponding to vector PGK) in which the PGK-1 promoter was replaced by ligating the 7.7 kb fragment obtained after EcoRV and BamHI digestion with, respectively, a 0.5 kb sequence of the WAS proximal promoter obtained as a ClaI-BamHI fragment of the 14 or the short intronless EF1-alpha promoter obtained as a XhoI-BamHI fragment of the pRRL sin cPPT EF1-GFP-WPRE vector, 16 or the SFFV LTR obtained as a ClaI-BamHI fragment of the pHR'sin18cppSWW vector. 14 The pRRL SIN cPPT/cTS W1.6-hWASp-ex12 WPRE plasmid (vector W1.6ex12) was constructed by exchanging the BspEI-SalI fragment with the pRRL SIN cPPT/cTS W0.5ex12-hWASp-WPRE plasmid, the latter differing from the pRRL SIN cPPT/ cTS W0.5-hWASp-WPRE plasmid by the removal of a short stretch of nucleotides (corresponding to a cloning site) inserted 5 0 of translation initiation. The two gene transfer cassettes of W1.6ex12 and W0.5ex12 are therefore identical except in length of promoter.
Generation and titration of lentiviruses
VSV-G-pseudotyped LV were produced by transient quadritransfection of 293T cells as previously described. 13 Titers (i.g./ml) were determined by quantitative PCR on genomic DNA of serially-infected HCT116 cells by quantifying proviral sequences in the Psi region normalized to the human albumin gene (ALB), using primers described in Table 4 and based on standard curves generated from the pRRLcpptPGKGFP-WPREAlb plasmid containing the appropriate sequences in cis from the vectors and ALB gene.
PCR primers and probes used in the study
All sequences are indicated in Table 4 .
Derivation, culture and transduction of cells from WAS patients
Blood and BM from WAS patients and normal donors were obtained according to approved research protocols after informed consent, following institutional and national ethical guidelines.
B cell lines. Epstein-Barr virus (EBV)-transformed
B-LCL were derived from peripheral blood (PB) MNC of WAS patients (Table 2) after infection with B95-8 cell supernatant in the presence of phytohemagglutinin (PHA) and cyclosporine, using standard procedures. Cells were grown at 371C, 5% CO 2 in RPMI-1640 medium supplemented with 10% fetal calf serum (FCS), penicillin-streptomycin and L-glutamine (R10 medium). B-LCL were transduced at the concentration of 2 Â 10 5 cells/ 0.2 ml per well in the presence of polybrene (6 mg/ml) for 6 h with various concentrations of vectors ranging from 0.5 Â 10 7 i.g./ml with a MOI (multiplicity of infection) 5 to 1 Â 10 8 i.g./ml with MOI 100. After transduction, cells were washed and incubated for 7-10 days, adding fresh medium every other day.
T cell lines. Untransformed T cell lines were derived as described previously from the peripheral blood mononuclear cells (PBMC) of a WAS patient previously referred to as WAS1. 12 Briefly, PBMC were stimulated by a feeder cell mixture comprising irradiated allogenic PBMC (1 Â 10 6 /ml), irradiated EBV-transformed JY cells (1 Â 10 5 /ml), PHA (1 mg/ml), IL-2 (100 IU/ml) and IL-7 (10 ng/ml). These allospecific T cells were cultured in IMDM medium, 10% FCS, penicillin/streptomycin, at 371C, 5% CO 2 and were stimulated every other week with the feeder cell mixture. Lentiviral transduction of T cells from the WAS patient was performed as previously described. 12 Briefly, T cells were prestimulated at 1 Â 10 6 cells/ml for 48 h with immobilized anti-CD3 mAb (1 mg/ ml), soluble anti-CD28 mAb (1 mg/ml), IL-2 (100 U/ml) and IL-7 (10 ng/ml). Transduction was performed by overnight incubation of prestimulated T cells (2 Â 10 5 cells in a volume of 0.5 ml) with vectors at the concentration 8 Â 10 6 i.g./ml (MOI 20) and 4 Â 10 7 i.g./ ml (MOI 100) in the presence of polybrene (8 mg/ml).
Jurkat-W8 cells. This cell line was produced as described. 18 Dendritic cells. Immature DC were obtained from an adherent cell fraction of BM. Briefly, BM-MNC obtained by density centrifugation were plated onto tissue culture plastic flasks for 2 h at 371C in R10 medium. Nonadherent cells were washed off and the remaining plastic-adherent cells were cultured at 371C in R10 medium supplemented with human recombinant granulocyte-monocyte colony-stimulating factor (GM-CSF) (50 ng/ml) and human IL-4 (20 ng/ml) (R&D Systems, Minneapolis, MN, USA). The following day, 1 Â 10 6 cells per well and per ml were transduced with 1 Â 10 8 i.g./ml of vector (MOI ¼ 100) in the presence of polybrene (4 mg/ ml), for 3 h. Fresh medium with GM-CSF and IL-4 was added and renewed every other day for 7 days. + cells were preactivated with the cytokines thrombopoietin (TPO) (100 ng/ml), stem cell factor (SCF) (300 ng/ml), flt-3-ligand (300 ng/ml) and IL-3 (60 ng/ml) in XVIVO medium (Cambrex, Belgium) for a day. In the set of experiments with WAS4 patient's CD34 + cells, the cells were then exposed onto retronectincoated plates, to the W1.6 LV at 2 Â 10 7 i.g./ml (or control PGK-GFP vector at 1 Â 10 8 TU/ml) either in a single hit (12 h-long exposure to LV and 36 h total time of culture) or in a double hit (12 h each interspaced by a recovery of 12 h and for a total time of culture of 60 h) using a MOI ¼ 100 for each infection. In the set of experiments with WAS5 patient's CD34 + cells, a single-hit protocol using the W1.6 or W0.5 LV at 5 Â 10 7 i.g./ml and MOI ¼ 400 with polybrene (6 mg/ml) was used. After the transduction, cells were washed and tested in various assays: CFU in culture (CFU-C), LTC-IC assays or were expanded for about 10 days in the cytokine-containing medium used for the transduction.
Cord blood progenitor cells. CD34 + cells were obtained from UCB-MNC by immunomagnetic selection (Miltenyi Biotec). For transduction, 5 Â 10 4 cells in 0.2 ml were preactivated by overnight incubation in medium supplemented with SCF (50 ng/ml) (R&D Systems), Flt-3 ligand (25 ng/ml) (Abcys SA, Paris, France), TPO (25 ng/ml) (kindly provided by Kirin Brewery, Gunma, Japan), IL-6 (10 ng/ml) (R&D Systems). Preactivated cells were then transduced with LV at 1 Â 10 8 i.g./ml (MOI 100) for 3-6 h in the presence of polybrene (6 mg/ ml). After the transduction, cells were washed and CFU-C assays were performed.
PCR analysis of transduction efficiency
The number of vector integrated per cell was measured by quantitative PCR detection of WPRE or Psi sequences normalized to ALB, as described for titrations, using genomic DNA extracted from transduced cells with the 'Wizard genomic DNA purification kit' (Promega Corporation, Madison, WI, USA). WAS mRNA expression was measured by quantitative RT-PCR normalized to expression of the transcription factor hTFIID. Total RNA was extracted with the SV total RNA isolation system (Promega) and 1 mg was reverse transcribed into cDNA with the Super-Script II RT (Gibco BRL, Paisley, UK) using random hexamer primers as described elsewhere. 33 Amplification reactions (17 ml) contained 8 ml of sample cDNA or genomic DNA and 9 ml of TaqMan buffer (TaqMan Universal PCR Master Mix, No AmpErase UNG, Applied Biosystems, Foster City, CA, USA), 0.2 mM primers (forward and reverse), 0.1 mM TaqMan probe (5 0 reporter dye (6-carboxyfluorescein) and a downstream, 3 0 quencher dye (6-carboxytetramethyl rhodamine)) and consisted of 40 cycles at 951C (15 s) then 601C (1 min) on an ABI PRISM 7700 sequence detector (Perkin-Elmer, Applied Biosystems). Standard amplification curves were obtained by serial dilutions of a known cDNA sample. All PCR measures were performed at least in duplicate. Data were edited using the Primer Express software. Results were expressed as the ratio of WAS mRNA to TFIID, which is highly stable in normal B-LCL (S Charrier, data not shown). The WAS/TFIID mRNA ratio obtained after transduction of patients' cells was normalized to that of a normal B-LCL control (arbitrary 100% value) versus the non-transduced cells (arbitrary 0% value).
Detection of WASp by intracellular immunofluorescence staining
Cells were suspended in phosphate-buffered saline (PBS) buffer containing 0.2% bovine serum albumin (BSA) and 0.02% NaN 3 were fixed and permeabilized with the Cytofix/Cytoperm kit (BD Biosciences Pharmingen, San Diego, CA, USA). Nonspecific binding was prevented by a 10 min blocking step with gamma-immune human normal immunoglobulin (IgG) (1 mg/ml, Sigma-Aldrich, St Louis, MO, USA) prior to incubating the cells for 30 min at 41C with PE-conjugated anti-WASp (B9, clone Santa Cruz Biotechnology, Santa Cruz, CA, USA) or with PE-IgG2a control antibodies diluted in saponin buffer (Caltag, Burlingame, CA, USA). T cells were fixed and permeabilized as above, but nonspecific binding was blocked with 5% normal rabbit serum and cells were incubated with 5 mg/ml of purified anti-WASp monoclonal antibody (mAb) 5A5 (kind gift from Dr S Tsuchyia, Tohoku University, Sendai, Japan) for 20 min at 41C. After washing, 5 mg/ml of PE-conjugated goat anti-mouse IgG Abs (Southern Biotechnology Associates, Birmingham, AL, USA) was added for 15 min at 41C. Stained cells were analyzed using a FACScan with CELLQuest software (BD Biosciences).
Western blot analysis
For Western blot analysis in Figures 2, 4 and 7c, cells were washed and lysed in buffer containing 50 mM TrisHCl pH 7.5, 200 mM NaCl, 1% Triton X-100, 0.1% sodium dodecyl sulfate (SDS), 0.5% sodium deoxycholate, 10% glycerol, 1 mM ethylene diaminetetraacetic acid (EDTA), 1 mM phenylmethylsulfonylfluoride (PMSF, Sigma) and a cocktail of protease inhibitors (Roche Diagnostics, Basel, Switzerland) consisting of leupeptin, pepstatin and aprotinin (10 mg/ml each). Lysates were boiled in the presence of 5 Â Laemmli buffer. Protein concentration was measured by colorimetry (BioRad Laboratories, Hercules, CA, USA) and 30 mg total protein was deposited per lane, separated by 10% SDS-polyacrylamide gel electrophoresis (PAGE), transferred onto nitrocellulose membranes (Hybond ECL, Amersham Biosciences, Piscataway, NJ, USA), blotted with a combination of mouse mAbs D1 specific for human WASp (Santa Cruz Biotechnologies, Santa Cruz, CA, USA) and AC-15 specific for human b-actin (SigmaAldrich, Saint Louis, MO, USA), detected with peroxidase-conjugated AffinityPure goat anti-mouse IgG secondary antibody (Jackson ImmunoResearch, West Grove, PA, USA), revealed by chemiluminescence (ECL Western blotting detection kit, Amersham, Piscataway, NJ, USA) and Kodak Biomax film (Sigma-Aldrich).
For Western blot analysis in Figures 3a and 7a , lysates were prepared from 1 Â 10 6 PBS-washed cells in 20 ml lysis buffer (20 mM Tris pH 7.5, 150 mM NaCl, 1% NP-40, 2 mM EDTA) supplemented with 100 mg/ml PMSF and protease inhibitors (Roche Diagnostics). Total protein concentration was determined with the BCA protein T cell proliferation and IL-2 production assay
For the proliferation assay, resting T cells (9-14 days poststimulation with feeder cell mixture) were harvested, centrifuged and incubated over-night at 2 Â 10 6 per ml in fresh medium without cytokine. They were plated at 1 Â 10 5 cells per well in 96-well flat-bottom plates precoated with the indicated dose of anti-CD3 mAbs. After 72 h, cells were labeled with 3 H-thymidine for 18 h and thymidine incorporation was measured in triplicates by liquid scintillation counting. IL-2 production was measured in the supernatants of cells that had been stimulated for 24 h with the indicated concentrations of immobilized anti-CD3 mAbs using capture enzyme-linked immunosorbent assay (ELISA) (BD Biosciences Pharmingen), peroxidase-conjugated streptavidin (Roche Diagnostics) and tetramethylbenzidine (Fluka Chemie, Switzerland) as substrate.
Detection of podosomes in dendritic cells
Preparations of immature dendritic cells were deposited onto glass coverslips coated with human fibronectin (coated at 100 ng/ml for 4 at 41C and washed with PBS) and cells were incubated for 2 h at 371C to allow adherence and formation of podosomes. Cells were then fixed in 2% paraformaldehyde for 10 min, washed with PBS and permeabilized using Triton X-100 (0.2%) for 4 min. Podosomes were detected with antibodies to vinculin (1:400, Sigma-Aldrich) revealed by secondary goat anti-mouse antibodies conjugated to Alexa 488 (1:1000, Molecular Probes, Invitrogen, Carlsbad, CA, USA) and with filamentous actin staining by tetramethylrhodamine-phalloidin (1:1000). Nuclei were labeled with DAPI in the Fluoromount G anti-fading mounting medium. Cells were examined by confocal microscopy using the Leica TCS SP2 AOBS laser scanning microscope. Imaging was performed with a Â 40 oil-immersion objective using the laser wavelengths 488 nm (argon), 543 nm (HeNe) excitation and 405 nm (diode laser). All images represent a single section through the focal plane. Images were processed with Leica TCS Start and Adobe Photoshop software. Percentage of cells displaying podosomes were counted by enumerating at least 100 cells using duplicate measures per sample.
CFU-C and LTC-IC assays
CFU-C assays were performed by plating 1000 transduced or untransduced cells per milliliter in methocult medium (H4434) (Stem Cell Technologies, Vancouver, CA, USA). After 2 weeks, CFU-E, BFU-E, CFU-GM and CFU-mix were counted. For the LTC-IC assay, 6 Â 10 5
CD34
+ cells were plated on irradiated fetal BM stroma in Myelocult medium (Stem Cell Technologies) as previously described. 34 After 5 weeks of culture, CD34 + cells were plated in CFU-C assays and colonies counted after 2 weeks.
Promoter sequence analysis
Annotation of the two human WAS promoter sequences (HWAS 1.6 and HWAS 0.5) was performed by combining several approaches. Three public data sources were used. Genbank (release 145.0) was downloaded from the National Center for Biotechnology Information (NCBI, ftp://ftp.ncbi.nih.gov/) and the GoldenPath annotations (build hg16) were downloaded from the University of California, Santa Cruz (UCSC, ftp://hgdownload.cse. ucsc.edu/goldenPath/hg16/database). JASPAR, the transcription factor binding profile database of the Karolinska institute (http://jaspar.cgb.ki.se), was consulted on-line. The WAS promoter known consensus binding sequences were obtained from Genbank (Accession Y16094.1) by using in-house keyword searching software.
